SMS Pharmaceuticals
NSE: SMSPHARMA · ISIN INE812G01025 · Healthcare
₹522.95+17.95 (+3.55%)
Monday 9 November, 12:46 IST. Delayed. Source: Yahoo Finance.
Price chart
₹522.95 +17.95 (+3.55%) today
The day
- Previous close
- ₹505.00
- Open
- ₹507.80
- Day high
- ₹533.50
- Day low
- ₹505.80
Listed on NSE since 28 February 2007.
Key numbers
- Market value
- ₹4,729.43 Cr
- P/E (trailing)
- 44.93
- EPS (trailing)
- ₹11.24
- Price to book
- 6.02
- Dividend yield
- 0.08%
- Debt to equity
- 0.46
- Profit margin
- 11.4%
- Beta
- 0.21
- Volume today
- 5.36 L
- Average volume
- 8.15 L
Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.
Revenue and profit
| Year | Revenue | Net profit |
|---|---|---|
| FY23 | ₹519.75 Cr | ₹-7.06 Cr |
| FY24 | ₹706.46 Cr | ₹49.83 Cr |
| FY25 | ₹779.27 Cr | ₹69.14 Cr |
| FY26 | ₹883.23 Cr | ₹101.99 Cr |
Source: Yahoo Finance, from annual reports. Consolidated where reported.
Quarterly results
| Quarter | Revenue | Net profit | Profit vs year ago |
|---|---|---|---|
| Q2 FY27Jul–Sep 2026 | ₹316 Cr | ₹40 Cr | +57.4% |
| Q1 FY27Apr–Jun 2026 | ₹207 Cr | ₹21 Cr | +2.0% |
| Q4 FY26Jan–Mar 2026Audited | ₹238 Cr | ₹33 Cr | −72.4% |
| Q3 FY26Oct–Dec 2025 | ₹210 Cr | ₹23 Cr | – |
| Q2 FY26Jul–Sep 2025 | ₹242 Cr | ₹25 Cr | – |
| Q1 FY26Apr–Jun 2025 | ₹196 Cr | ₹20 Cr | – |
Source: SMS Pharmaceuticals’s results filed with NSE, consolidated (the whole group). Net profit is the share of SMS Pharmaceuticals’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.
Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.
Balance sheet
| As on | September 2026 | March 2026 |
|---|---|---|
| Fixed assets | ₹718 Cr | ₹653 Cr |
| Investments | ₹28 Cr | ₹26 Cr |
| Inventories | ₹378 Cr | ₹351 Cr |
| Owed by customers | ₹243 Cr | ₹216 Cr |
| Cash and equivalents | ₹36 Cr | ₹46 Cr |
| Total assets | ₹1,461 Cr | ₹1,362 Cr |
| Borrowings | ₹349 Cr | ₹365 Cr |
| Total liabilities | ₹618 Cr | ₹577 Cr |
| Shareholders’ equity | ₹843 Cr | ₹786 Cr |
Source: SMS Pharmaceuticals’s half-yearly statements of assets and liabilities filed with NSE, consolidated. Companies file these every September and March.
About SMS Pharmaceuticals
SMS Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients (APIs) and its intermediates in India and internationally. It offers anti-retroviral, anti-inflammatory, anti-viral, anti-diabetic, anti-fungal, anti-epileptic, anti-migraine, anti-coagulant, anti-psychotic, anti-aginal, and anti-ulcer products. It is also involved in contract research activities on peptides. The company exports its products to approximately 75 countries. SMS Pharmaceuticals Limited was incorporated in 1987 and is headquartered in Hyderabad, India.
- Industry
- Drug Manufacturers - General
- Based in
- Hyderabad
- Employees
- 1,617
Company website · Profile: Yahoo Finance
In the news
All newsNo headlines name SMS Pharmaceuticals in the last day or two.
Dividends and corporate actions
All companies- Dividend - Re 0.40 Per Share
Dividend · ex-date 22 September 2026
- Dividend - Re 0.40 Per Share
Dividend · ex-date 22 September 2025
- Dividend - Rs 0.40 Per Share
Dividend · ex-date 23 September 2024
- Annual General Meeting
Action · ex-date 23 September 2024
- Dividend - Re 0.30 Per Share
Dividend · ex-date 22 September 2023
- Annual General Meeting
Action · ex-date 22 September 2023
- Dividend - Re 0.30 Per Share
Dividend · ex-date 22 September 2022 · record date 23 September 2022
- Annual General Meeting
Action · ex-date 22 September 2022
Source: NSE. Latest first, 8 of 20.
Information only, not investment advice. Prices are delayed.